Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K8RK
|
|||
| Drug Name |
Alisporivir
|
|||
| Synonyms |
DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 3 | [1] | |
| Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Investigative | [2], [3] | ||
| Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Investigative | [3] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Canonical SMILES |
CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
|
|||
| CAS Number |
CAS 254435-95-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN cyclophilin A (CYPA) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01500772) Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C | |||
| REF 2 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | |||
| REF 3 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.